Abstract Title:

Cannabidiol and Neurodegeneration: From Molecular Mechanisms to Clinical Benefits.

Abstract Source:

Ageing Res Rev. 2024 Jul 3:102386. Epub 2024 Jul 3. PMID: 38969143

Abstract Author(s):

Saurabh Kumar Jha, Vinod Kumar Nelson, Punna Rao Suryadevara, Siva Prasad Panda, Chitikela P Pullaiah, Mohana Vamsi Nuli, Mehnaz Kamal, Mohd Imran, Saijyothi Ausali, Mosleh Mohammad Abomughaid, Rashi Srivastava, Rahul Deka, Pingal Pritam, Neha Gupta, Harishankar Shyam, Indrakant K Singh, Bindhy Wasini Pandey, Saikat Dewanjee, Niraj Kumar Jha, Seid Mahdi Jafari

Article Affiliation:

Saurabh Kumar Jha


Neurodegenerative disorders (NDs) such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, and amyotrophic lateral sclerosis are severe and life-threatening conditions in which significant damage of functional neurons occurs to produce malfunction of psycho-motor functions. NDs are an important cause of death in the elderly population worldwide. These disorders are commonly associated with the progression of age, oxidative stress, and environmental pollutants, which are the major etiological factors. Abnormal aggregation of specific proteins such asα-synuclein, amyloid-β, huntingtin, and tau, and accumulation of its associated oligomers in neurons are the hallmark pathological features of NDs. Existing therapeutic options for NDs are only symptomatic relief and do not address root-causing factors, such as protein aggregation, oxidative stress, and neuroinflammation. Cannabidiol is a non-psychotic natural cannabinoid obtained from Cannabis sativa that possesses multiple pharmacological actions, including antioxidant, anti-inflammatory, and neuroprotective effects in various NDs and other neurological disorders both in vitro and in vivo. Cannabidiol has gained attention as a promising therapeutic drug candidate for the management of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, by inhibiting protein aggregation, free radicals, and neuroinflammation. In parallel, CBD has shown positive results in other neurological disorders, such as epilepsy, depression, schizophrenia, and anxiety, as well as adjuvant treatment with existing standard therapeutic agents. Hence, the present review focuses on exploring the possible molecular mechanisms in controlling various neurological disorders as well as its clinical applications in NDs including epilepsy, depression and anxiety. In this way, the current review will serve as a standalone reference for the researchers working in this area.

Print Options

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.